Clinical Trials on Thrombocytosis

Total 196 results

Inge Marie Svane

Completed

Dual Vaccine Trial in Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia

Denmark
Exelixis

Terminated

A Safety Study of XL019 in Adults With Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Thrombocythemia, Essential | Myelofibrosis

United States
Terrence J Bradley, MD
Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New...

Recruiting

IMG-7289 in Patients With Essential Thrombocythemia (ET) or Polycythemia Vera (PV)

Polycythemia Vera | Essential Thrombocythemia

United States
Dr Yan Beauverd

Completed

Treatment of Polycythaemia Vera and Essential Thrombocythaemia: Influence on the Clot Structure (MPNClot)

Polycythemia Vera | Thrombocythemia, Essential

Switzerland, United Kingdom
Sierra Oncology, Inc.

Terminated

Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States, France, Germany, Canada, Australia
Icahn School of Medicine at Mount Sinai
The Leukemia and Lymphoma Society

Completed

Tissue Banking Study - Polycythemia Vera or Essential Thrombocythemia (PV & ET) Patients

Polycythemia Vera | Essential Thrombocythemia

United States
University Medical Centre Ljubljana

Completed

Arterial Function and Atherosclerosis in Essential Thrombocythemia

Atherosclerosis
Hamad Medical Corporation

Unknown

18F-FLT (PET/CT) in Prefibrotic/Early Primary Myelofibrosis and Essential Thrombocythemia (PMF/ET-FLT)

Essential Thrombocythemia | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

Qatar
Queen's University, Belfast
Mayo Clinic; University Hospital Southampton NHS Foundation Trust; University... and other collaborators

Completed

Myeloproliferative Neoplasms: an In-depth Case-control Study (MOSAICC)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United Kingdom
Celgene

Active, not recruiting

A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

Primary Myelofibrosis

Japan
University Hospital, Bordeaux

Completed

Endoplasmic Reticulum Stress and Resistance to Treatments in Ph-negative Myeloproliferative Neoplasms (PhiNESS)

Polycythemia Vera | Essential Thrombocythemia

France
Sanofi

Completed

Study With SAR302503 in Patients With Polycythemia Vera or Essential Thrombocythemia

Hematopoietic Neoplasm

United States, Spain, France, Canada, Australia, Korea, Republic of, Germany, Italy, United Kingdom
Massachusetts General Hospital
Incyte Corporation

Recruiting

Ruxolitinib in Thrombocythemia and Polycythemia Vera

Polycythemia Vera | Essential Thrombocythemia

United States
University Hospital, Angers

Recruiting

Pilot Study for the Development of a Diagnostic Score to Differentiate Myeloproliferative Neoplasms. (BioScoreSMP)

Essential Thrombocythemia | Myeloproliferative Disorder | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
John Mascarenhas
Roche Pharma AG; The Leukemia and Lymphoma Society

Completed

Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia

Polycythemia Vera | Essential Thrombocythemia

United States
University Hospital, Brest

Completed

Drug Observance and Side Effects of Cytoreductive Drugs in PV and ET Patients (OUEST)

Polycythemia Vera | Essential Thrombocythemia

France
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Active, not recruiting

An Efficacy and Safety Study of Fedratinib Compared to Best Available Therapy in Subjects With DIPSS-intermediate or High-risk Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM2)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera

Australia, Austria, Belgium, China, Czechia, France, Germany, Hungary, Italy, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Ireland, United Kingdom
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Familial Myeloproliferative Disorders

Polycythemia Vera | Essential Thrombocythemia | Idiopathic Myelofibrosis

United States, Italy
Novartis Pharmaceuticals

Completed

A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

Primary Myelofibrosis (MF)

Japan
Novartis Pharmaceuticals

Completed

Exploratory Phase II Study of INC424 Patients With Primary Myelofibrosis (PMF) or Post Polycythaemia Myelofibrosis (PPV MF) or Post Essential Thrombocythaemia Myelofibrosis (PET-MF) (MACS2030)

Primary Myelofibrosis (PMF) | Post Polycythaemia Myelofibrosis (PPV MF) | Post Essential Thrombocythaemia Myelofibrosis (PET-MF)

United Kingdom
Kartos Therapeutics, Inc.

Recruiting

An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 Combined With Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera MF (Post-PV-MF), Or Post-Essential Thrombocythemia MF (Post ET-MF) Who Have a Suboptimal Response to Ruxolitinib

Myelofibrosis

United States, France, Australia, Spain, Germany, Bulgaria, Israel, Italy, Poland
Roswell Park Cancer Institute
Cephalon, Inc.

Terminated

Arsenic Trioxide With or Without Ascorbic Acid in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
Gilead Sciences

Terminated

Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Idelalisib in Adults Receiving Ruxolitinib as Therapy for Primary, Post-Polycythemia Vera, or Post-Essential Thrombocythemia Myelofibrosis With Progressive or Relapsed Disease (Madison)

Myelofibrosis

United States
Eli Lilly and Company

Completed

Study of LY573636-sodium in Essential Thrombocythemia and Acute Myeloid Leukemia

Acute Myeloid Leukemia | Essential Thrombocythemia

United States
Memorial Sloan Kettering Cancer Center
Novartis

Terminated

HSP90 Inhibitor, AUY922, in Patients With Primary Myelofibrosis (PMF), Post-Polycythemia Vera Myelofibrosis (Post-PV MF), Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), and Refractory PV/ET

Myeloproliferative Neoplasms

United States
Ronald Hoffman
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Unknown

CEP-701 (Lestaurtinib) in Myelofibrosis

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
University Hospital, Brest

Recruiting

Myeloproliferative Neoplastic Diseases Observatory From Brest (OBENE)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

France
Incyte Corporation

Completed

Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia Myelofibrosis

Polycythemia Vera | Thrombocytosis | Myelofibrosis

United States
University Hospital, Angers
Poitiers University Hospital; University Hospital, Brest; Rennes University Hospital and other collaborators

Not yet recruiting

Identification of Factors Associated With Treatment Response in Patients With Polycythemia Vera, Essential Thrombocythemia, and Pre-myelofibrosis. (BioPredictor)

Myeloproliferative Neoplasm
Ronald Hoffman
National Cancer Institute (NCI); Roche Pharma AG; Myeloproliferative Disorders-Research...

Completed

Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET)

High Risk Polycythemia Vera | High Risk Essential Thrombocythemia

United States, Italy, United Kingdom, France
RWTH Aachen University
Novartis Pharmaceuticals

Active, not recruiting

The Ruxo-BEAT Trial in Patients With High-risk Polycythemia Vera or High-risk Essential Thrombocythemia (Ruxo-BEAT)

Polycythemia Vera (PV) | Essential Thrombocythemia (ET)

Germany
Thomas Stauffer Larsen

Completed

A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms (DALIAH)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

Denmark
Syntara
Parexel

Recruiting

Study to Evaluate Safety, Pharmacokinetic and Pharmacodynamic Dose Escalation and Expansion Study of PXS-5505 in Patients With Primary, Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis

Myelofibrosis

Taiwan, Australia, Korea, Republic of, United States
Gilead Sciences

Completed

Efficacy and Safety of Simtuzumab in Adults With Primary, Post Polycythemia Vera or Post Essential Thrombocythemia Myelofibrosis

Myelofibrosis

United States
University of Utah
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Polycythemia Vera, Myelofibrosis and Essential Thrombocythemia: Identification of PV, MF & ET Genes

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States
S*BIO

Completed

A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis

Myeloproliferative Disorders | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis

United States, Australia
University Hospital, Angers

Not yet recruiting

Functional and Phenotypic Characterization of Monocytes in Myeloproliferative Syndromes (PHEMOP)

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

France
Sierra Oncology LLC - a GSK company

Completed

Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, France, Canada, Germany, Australia
Swiss Group for Clinical Cancer Research

Completed

Sympathicomimetic Agonist in Patients With Myeloproliferative Neoplasms With JAK2-mutation

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia | Myeloproliferative Neoplasm

Switzerland
Sierra Oncology, Inc.

Completed

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)

Primary Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-Essential Thrombocythemia Myelofibrosis

United States, Canada, Australia
National Cancer Institute (NCI)

Completed

Lenalidomide and Prednisone in Treating Patients With Myelofibrosis

Primary Myelofibrosis | Polycythemia Vera | Essential Thrombocythemia

United States
University Hospital, Angers
Ligue contre le cancer, France

Recruiting

Interest of CALR Allele Burden in Diagnosis and Follow-up of Patients With CALR Mutated Myeloproliferative Syndromes (CALRSUIVI) (CALRSUIVI)

Essential Thrombocythemia | Myeloproliferative Neoplasm | Primary Myelofibrosis, Prefibrotic Stage | Primary Myelofibrosis, Fibrotic Stage

France
Incyte Corporation

Terminated

Study to Determine the Safety and Efficacy of INCB018424 in Patients With Polycythemia Vera or Essential Thrombocythemia

Myeloproliferative Neoplasm (MPN)

United States, Italy
Icahn School of Medicine at Mount Sinai
National Cancer Institute (NCI); Myeloproliferative Disorders-Research Consortium

Completed

Research Tissue Bank

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Idiopathic Myelofibrosis

United States, Italy
Eli Lilly and Company

Completed

Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloproliferative Neoplasms of

United States
Hangzhou GluBio Pharmaceutical Co., Ltd.

Not yet recruiting

A Study of GLB-001 in Patients With Myeloid Malignancies

Acute Myeloid Leukemia | Myelodysplastic Syndromes | Polycythemia Vera | Essential Thrombocythemia | Myelofibrosis | Myeloid Malignancy

China
Bristol-Myers Squibb

Recruiting

A Post-Marketing Surveillance Study to Assess the Safety of Fedratinib in Korean Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Korea, Republic of
Gruppo Italiano Malattie EMatologiche dell'Adulto

Recruiting

Real World Evidence of Fedratinib Effectiveness in MF (REALFed)

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

Italy
NS Pharma, Inc.
Nippon Shinyaku Co., Ltd.

Recruiting

Study to Assess Efficacy and Safety of NS-018 Compared to BAT in Patients With Myelofibrosis

Primary Myelofibrosis | Post-polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Korea, Republic of, Malaysia, Italy, Germany, Poland, United Kingdom, Thailand, Turkey
Celgene
Impact Biomedicines, Inc., a wholly owned subsidiary of Celgene Corporation

Completed

A Trial of Fedratinib in Subjects With DIPSS, Intermediate or High-Risk Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocythemia Myelofibrosis and Previously Treated With Ruxolitinib (FREEDOM)

Primary Myelofibrosis | Myelofibrosis | Post-Polycythemia Vera Myelofibrosis | Post-essential Thrombocythemia Myelofibrosis

United States, Canada

Clinical Trials on Thrombocytosis

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Germany

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations